In addition, TP53 mutations and HER2 amplifications may promote the malignant progression of ovarian borderline mucinous tumors (Cheasley et al., 2019; Hada et al., 2023). This evidence concerns the gene TP53 and Borderline Ovarian Mucinous Tumor.